MBCL-26. FACTORS ASSOCIATED WITH LONGER SURVIVAL AFTER FIRST RECURRENCE IN MEDULLOBLASTOMA BY MOLECULAR SUBGROUP AFTER RISK-BASED INITIAL THERAPY
Sign Up to like & getrecommendations! Published in 2020 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaa222.502
Abstract: Abstract OBJECTIVE To evaluate differences in time to recurrence among molecular subgroups of medulloblastoma treated on a single protocol and to identify factors associated with survival after first recurrence. METHODS Time to recurrence following SJMB03… read more here.
Keywords: first recurrence; risk; recurrence; value ... See more keywords
Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden.
Sign Up to like & getrecommendations! Published in 2019 at "Neuro-oncology practice"
DOI: 10.1093/nop/npy021
Abstract: Background Since its approval for use in recurrent glioblastoma (GBM), the survival benefit of bevacizumab (Bev) remains to be demonstrated. To address this issue, we retrospectively examined survival from first recurrence in patients treated with… read more here.
Keywords: first recurrence; patients large; bev; tumor ... See more keywords
Abstract CT103: Final results for OptimalTTF-1: Optimizing Tumor Treating Fields with targeted skull remodeling surgery for first recurrence glioblastoma: Phase 1 trial
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-ct103
Abstract: Background: We present a clinical open label, phase-1 trial (OptimalTTF-1, NCT02893137), which aims to test a novel treatment for first recurrence glioblastoma (rGBM). The aim of the treatment is to optimize the electric field generated… read more here.
Keywords: first recurrence; surgery; trial; recurrence glioblastoma ... See more keywords
Phase II study of pembrolizumab plus SurVaxM for glioblastoma at first recurrence.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.tps2581
Abstract: TPS2581Background: Glioblastoma is the most common primary malignant brain tumor with median survival of approximately 15-16 months. Following first recurrence, progression free survival at six mon... read more here.
Keywords: first recurrence; glioblastoma; pembrolizumab plus; study pembrolizumab ... See more keywords